Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Dennen, Paula ^a   Altmann, Christopher ^b   Kaufman, Jonathan ^c   Klein, Christina L ^d   Andres Hernando, Ana ^b   Ahuja, Nilesh H ^b   Edelstein, Charles L ^b   Cadnapaphornchai, Melissa A ^c   Keniston, Angela ^b   Faubel, Sarah ^b  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CREATININE; CYTOKINE; FUROSEMIDE; INTERLEUKIN 6;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION; HEART SURGERY; HUMAN; INFANT; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UREMIA; ADOLESCENT; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; NEWBORN; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; TIME; URINE;

ACUTE KIDNEY INJURY; ADOLESCENT; ANIMALS; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 77957732879     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9289     Document Type: Article

References (31)

1. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL, Macias WL. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007, 2:22-30. 10.2215/CJN.02510706, 17699383.
2. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC, . GenIMS Investigators Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177:1242-1247. 10.1164/rccm.200712-1777OC, 2720087, 18369199, GenIMS Investigators.
3. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA, . PICARD Study Group Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004, 65:1357-1365. 10.1111/j.1523-1755.2004.00512.x, 15086475, PICARD Study Group.
4. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995, 107:1062-1073. 10.1378/chest.107.4.1062, 7705118.
5. Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005, 23:488-493.
6. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, . Wheeler AP; NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005, 33:1-6. discussion 230-232, 10.1097/01.CCM.0000149854.61192.DC, 15644641, Wheeler AP; NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network.
7. Marcucci R, Gori AM, Giannotti F, Baldi M, Verdiani V, Del Pace S, Nozzoli C, Abbate R. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006, 4:1017-1022. 10.1111/j.1538-7836.2006.01916.x, 16689753.
8. Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006, 34:2035-2042. 10.1097/01.CCM.0000228919.33620.D9, 16775569.
9. Liu KD, Altmann C, Smits G, Krawczeski CD, Edelstein CL, Devarajan P, Faubel S. Serum Interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care 2009, 13:R104. 10.1186/cc7940, 2750143, 19570208.
10. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B, Nagami GT, Lu CY. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol 2005, 16:3315-3325. 10.1681/ASN.2003090757, 16192425.
11. Rachmawati H, Beljaars L, Reker-Smit C, Van Loenen-Weemaes AM, Hagens WI, Meijer DK, Poelstra K. Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm Res 2004, 21:2072-2078. 10.1023/B:PHAM.0000048199.94510.b0, 15587930.
12. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996, 16:1-11.
13. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990, 2:416-422. 10.1016/1043-4666(90)90050-4, 2104235.
14. Tanaka H, Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res 1990, 50:6615-6619.
15. Bocci V. Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 1991, 21:274-284. 10.2165/00003088-199121040-00004, 1760900.
16. Hepburn TW, Hart TK, Horton VL, Sellers TS, Tobia LP, Urbanski JJ, Shi W, Davis CB. Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. J Pharmacol Exp Ther 2001, 298:886-893.
17. Hoke TS, Douglas IS, Klein CL, He Z, Fang W, Thurman JM, Tao Y, Dursun B, Voelkel NF, Edelstein CL, Faubel S. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol 2007, 18:155-164. 10.1681/ASN.2006050494, 17167117.
18. Klein CL, Hoke TS, Fang WF, Altmann CJ, Douglas IS, Faubel S. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int 2008, 74:901-909. 10.1038/ki.2008.314, 18596724.
19. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 2007, 322:8-15. 10.1124/jpet.107.119792, 17400889.
20. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 2004, 66:2202-2213. 10.1111/j.1523-1755.2004.66010.x, 15569309.
21. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004, 286:F590-596. 10.1152/ajprenal.00324.2003, 14600035.
22. Faubel S, Ljubanovic D, Poole B, Dursun B, He Z, Cushing S, Somerset H, Gill RG, Edelstein CL. Peripheral CD4 T-cell depletion is not sufficient to prevent ischemic acute renal failure. Transplantation 2005, 80:643-649. 10.1097/01.tp.0000173396.07368.55, 16177639.
23. American Society of Nephrology American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005, 16:1886-1903. 10.1681/ASN.2005030285, 15888557, American Society of Nephrology.
24. Molitoris BA. Transitioning to therapy in ischemic acute renal failure. J Am Soc Nephrol 2003, 14:265-267. 10.1097/01.ASN.0000048852.53881.D9, 12506160.
25. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010, 77:1020-1030. 10.1038/ki.2010.25, 20164823.
26. Dennen P, Douglas IS, Anderson R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med 2010, 38:261-275. 10.1097/CCM.0b013e3181bfb0b5, 19829099.
27. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967, 126:207-221. 10.1084/jem.126.2.207, 2138312, 4165739.
28. Carone FA, Peterson DR, Oparil S, Pullman TN. Renal tubular transport and catabolism of proteins and peptides. Kidney Int 1979, 16:271-278. 10.1038/ki.1979.129, 529676.
29. Castell JV, Geiger T, Gross V, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988, 177:357-361. 10.1111/j.1432-1033.1988.tb14384.x, 3263918.
30. Kwon O, Molitoris BA, Pescovitz M, Kelly KJ. Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am J Kidney Dis 2003, 41:1074-1087. 10.1016/S0272-6386(03)00206-3, 12722043.
31. Molls RR, Savransky V, Liu M, Bevans S, Mehta T, Tuder RM, King LS, Rabb H. Keratinocyte-derived chemokine is an early biomarker of ischemic acute kidney injury. Am J Physiol Renal Physiol 2006, 290:F1187-1193. 10.1152/ajprenal.00342.2005, 16368740.